JP Morgan Chase
KRSA

JP Morgan Chase’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

JP Morgan Chase’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-295
Closed -$127K – 6691
2021
Q3 		$127K Sell
295
-132
-31% -$60.5K ﹤0.01% 5449
2021
Q2 		$233K Sell
427
-331
-44% -$145K ﹤0.01% 5154
2021
Q1 		$296K Buy
758
+122
+19% +$64.1K ﹤0.01% 4973
2020
Q4 		$273K Buy
636
+292
+85% +$139K ﹤0.01% 4692
2020
Q3 		$332K Buy
344
+290
+537% +$232K ﹤0.01% 4160
2020
Q2 		$44K Hold
54
– – ﹤0.01% 4866
2020
Q1 		$20K Sell
54
-7
-11% -$3.5K ﹤0.01% 4948
2019
Q4 		$23K Buy
61
+2
+3% +$1.31K ﹤0.01% 5298
2019
Q3 		$101K Buy
59
+6
+11% +$9.07K ﹤0.01% 4900
2019
Q2 		$83K Buy
+53
New +$105K ﹤0.01% 4997

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase's KRSA Position: Q4 2021 in Review

JP Morgan Chase sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2021, closing a stake of 295 shares — an estimated $127K sold.

JP Morgan Chase first reported a position in KRSA in Q2 2019 and held it in 10 quarters. The position peaked at $332K in Q3 2020. 51 funds tracked by Wall St. Rank hold KRSA as of Q4 2021.

  • JP Morgan Chase reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 295 Korsana Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $127K.
  • JP Morgan Chase first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
  • JP Morgan Chase's Korsana Biosciences, Inc. Common Stock position peaked at $332K in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.